Recent Updates
Recently added Catalysts
ALT Positive Sentiment Score: 70/100

Altimmune to Participate at Two Upcoming Investor Conferences

Monday, May 8, 2023 1 min read
Key Takeaway: Altimmune, Inc. has announced its participation in two upcoming investor conferences, emphasizing its commitment to engaging with investors. The JMP Securities Life Sciences Conference will take place on May 16, 2023, while the Piper Sandler Spring Biopharma Symposium is set for May 18, 2023. The focus of the company includes the development of innovative treatments for obesity and liver diseases, with its lead candidate, pemvidutide, currently in progress. The events highlight Altimmune's strategy to enhance visibility and discuss its clinical advancements.

Market Sentiment Analysis

POSITIVE FACTORS

  • Altimmune is actively participating in investor conferences, indicating growth and engagement.
  • The company is focused on developing novel therapeutics for significant health issues such as obesity and liver diseases.
  • The lead product candidate, pemvidutide, represents advancements in obesity treatment.

Full Press Release Details

GAITHERSBURG, Md., May 08, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:
JMP Securities Life Sciences Conference in New York, NY
Tuesday, May 16, 2023
Fireside chat at 9:00 am Eastern Time
The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.
Piper Sandler Spring Biopharma Symposium in Boston, MA
Thursday, May 18, 2023
One-on-one meetings only
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Altimmune Investor & Media Contact:
Chief Financial Officer
reisenstadt@altimmune.com

Frequently Asked Questions

When will Altimmune participate in investor conferences?

Altimmune will participate in investor conferences on May 16 and May 18, 2023.

What is Altimmune's lead product candidate?

Altimmune's lead product candidate is pemvidutide, a dual receptor agonist.

What conditions does pemvidutide aim to treat?

Pemvidutide is being developed for obesity and non-alcoholic steatohepatitis (NASH).

What is HepTcell™ designed for?

HepTcell™ is an immunotherapeutic aimed at achieving a functional cure for chronic hepatitis B.

How can I access the webcast for the fireside chat?

The webcast can be accessed in the Events section of the Altimmune website.

Tags: ALT Viatris Investor Conferences Healthcare Altimmune pemvidutide obesity liver diseases NASH
Last updated: May 8, 2023